Aspirin-Myocardial Infarction Study (AMIS)

Summary

To determine whether the daily administration of 1 gm of aspirin to individuals with a documented myocardial infarction would result in a significant reduction in mortality over a three year period.

Conditions

• Cardiovascular Diseases
• Coronary Disease
• Heart Diseases
• Myocardial Infarction
• Myocardial Ischemia

Interventions

DRUG

aspirin

Sponsors & Collaborators

• National Heart, Lung, and Blood Institute (NHLBI)

  lead NIH

Principal Investigators

• Allan Barker · Salt Lake Clinic Research Foundation

• David Berkson · Unity Health Toronto

• William Berstein · Icahn School of Medicine at Mount Sinai

• Nemat Borhani · University of California, Davis

• Elmer Cooper · Santa Rosa Medical Center

• Leonard Dreifus · Lankenau Hospital

• Noble Fowler · University of Cincinnati

• Phillip Frost · USPHS Hospital

• Mario Garcia-Palmieri · University of Puerto Rico Medical Science Campus

• Hugh Gilmore · University of Miami

• Sidney Goldstein · Henry Ford Hospital

• Olga Haring · Northwestern University

• J. Hoover · University of Washington

• Richard Hutchinson · University of Mississippi Medical Center

• William Krol · University of Maryland at Baltimore

• Peter Kuo · Rutgers Medical School

• Charles, Laubach · Institute for Medical Education and Research

• Bernard Lewis · Palo Alto Medical Research Foundation

• Jessie Marmorston · University of Southern California

• J. McNamara · Pacific Health Research Institute

• Dayton Miller · U.S. Centers for Disease Control and Prevention

• Thaddeus Prout · Greater Baltimore Medical Center

• David Richardson · Virginia Commonwealth University

• Jorge Rios · George Washington University

• Paul Samuel · Long Island Jewish-Hillside Medical Center

• Stephen Scheidt · Weill Medical College of Cornell University

• Robert Schlant · Emory University

• Henry Schoch · University of Michigan

• James Schoenberger · Rush University Medical Center

• Marvin Segal · MOUNT SINAI HOSPITAL

• Pantel Vokonas · Boston Health and Hospitals Department

• C. Williams · Ogden Research Foundation

• Gary Wilner · Endeavor Health

Study Design

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Eligibility

Min Age

30 Years

Max Age

69 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

1974-10-31

Completion

1979-08-31